UDR, Inc. Declares Quarterly Dividends

DENVER--(BUSINESS WIRE)-- UDR, Inc. (NYSE: UDR), a leading multifamily real estate investment trust, today announced that its Board of Directors declared a regular quarterly dividend on its common stock for the fourth quarter of 2025 in the amount of $0.43 per share, payable in cash on February 2, 2026 to UDR common stock shareholders of record as of January 12, 2026. The February 2, 2026 dividend will be the 213th consecutive quarterly dividend paid by the Company on its common stock.

UDR also announced that its Board of Directors declared a regular quarterly dividend on its Series E preferred stock for the fourth quarter of 2025 in the amount of $0.4656 per share. The preferred dividend is payable on February 2, 2026 to Series E preferred stock shareholders of record as of January 12, 2026.

About UDR, Inc.

UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S. markets. As of September 30, 2025, UDR owned or had an ownership position in 60,535 apartment homes, including 300 apartment homes under development. For over 53 years, UDR has delivered long-term value to shareholders, the best standard of service to residents and the highest quality experience for associates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251218184906/en/

UDR, Inc.
Trent Trujillo
[email protected]
720-283-6135

Source: UDR, Inc.

You May Also Be Interested In

• Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State Street
• Ride-Hailing Market Size to Reach USD 513.77 Billion by 2031, Driven by Urban Mobility Demand and Digital Booking Platforms – Mordor Intelligence
• Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy